U
EPZM

UBS’s Epizyme, Inc EPZM Stock Holding History

UBS’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Sell
200
-100
-33% -$3.11K ﹤0.01% 9510
2014
Q2 		$9K Buy
+300
New +$7.07K ﹤0.01% 9017

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS's EPZM Position: Q3 2014 in Review

UBS increased its Epizyme, Inc (EPZM) stake by 35% in Q3 2014, buying an estimated $35.1K and bringing the position to 4,339 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #5792.

UBS first reported a position in EPZM in Q3 2013 and has held it in 5 quarters since. The position peaked at $350K in Q3 2013. 94 funds tracked by Wall St. Rank hold EPZM as of Q3 2014.

  • UBS held 4,339 shares of Epizyme, Inc worth $118K as of Q3 2014.
  • UBS bought 1,130 Epizyme, Inc shares in Q3 2014, an estimated $35.1K.
  • Epizyme, Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5792 holding.
  • UBS first reported a position in Epizyme, Inc in Q3 2013 and has held it in 5 quarters since.
  • UBS's Epizyme, Inc position peaked at $350K in Q3 2013.
  • 94 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.